search
Back to results

Darusentan Effect on PET Uptake Heterogeneity (Darusentan)

Primary Purpose

Coronary Artery Disease, Endothelial Dysfunction

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
darusentan 100 mg
Sponsored by
K.Lance Gould
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring atherosclerosis, coronary artery disease, myocardial perfusion defect, endothelial dysfunction, endothelin receptor blockade

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subjects must be competent to provide written informed consent. Subjects must sign an IRB approved ICF and HIPAA Authorization prior to the initiation of any study procedures. All men must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking study drug, and queried regarding their understanding of the potential risks as described in the ICF.
  2. Subjects must be greater than 18 years of age.
  3. Female subjects must be surgically sterile or documented as post-menopausal for at least 2 years.
  4. Subjects must have documented coronary artery disease as evidenced by previous myocardial infarction, interventional procedure, significant stenosis by cardiac catheterization, or an abnormal perfusion study.
  5. Subjects must have an abnormal PET scan.

Exclusion Criteria:

  1. Subjects with acute heart failure
  2. Subjects with sustained or symptomatic hypotension (SBP 90 mmHg)
  3. Subjects with uncontrolled hypertension (SBP of 170 mmHg or DBP of 100 mmHg) at Screening
  4. Subjects with unstable angina pectoris
  5. Subjects with acute myocardial infarction, stroke, transient ischemic attack, or coronary angioplasty within the last 6 months
  6. Subjects with primary valvular disease
  7. Subjects with significant vascular aneurysm
  8. Subjects with a documented history of renal failure
  9. Subjects with liver disease (total bilirubin 3 mg/dL or serum ALT or AST >2X ULN)
  10. Subjects with active malignancy
  11. Subjects with a fatal non-cardiovascular disease that they are expected to succumb to within 1 year
  12. Female subjects that are pregnant or lactating
  13. Female subjects with the potential for child-bearing
  14. Female subjects being treated with hormone therapies
  15. Subjects with uncontrolled diabetes mellitus
  16. Subjects with diabetes with gastro paresis or severe neuropathy
  17. Subjects with a history of substance abuse within the last 2 years
  18. Subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the Screening Visit
  19. Subjects with known hypersensitivity or allergy to L-arginine, aminophylline, adenosine, or dipyridamole
  20. Subjects who have a planned surgical procedure during the course of the study
  21. Subjects taking herbal food supplements (L-carnitine, L-arginine or Ginko biloba)
  22. Subjects with known active or dormant type 2 herpes simplex virus infections
  23. Subjects with a contraindication to treatment with an ERA. Contraindications may include, but are not limited to, evidence of elevated liver function tests (e.g., aminotransferases >2X ULN) or an event defined as a serious adverse event attributed to previous treatment with an ERA
  24. Subjects who are judged by the investigator to be ineligible for this study for any other reason

Sites / Locations

  • Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group 1

Group 2

Arm Description

Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.

Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2

Outcomes

Primary Outcome Measures

Change During Darusentan Treatment in the Markovian Homogeneity Number, a Value That Quantitates Myocardial Perfusion Heterogeneity
Markovian homogeneity analysis characterizes an image produced by a PET scan by examining the probability that a pixel with a given intensity will have a neighbor with a different intensity. The homogeneity index ranges from >0 to 1, where a value near 0 represents an image with a high probability that neighboring pixels have intensity values that differ greatly, and a value near 1 represents an image with a high probability that neighboring pixels have similar intensity values.

Secondary Outcome Measures

Change During Darusentan Treatment in Absolute Flow at Rest and Hyperemia
Change During Darusentan Treatment in the Coronary Flow Reserve (CFR)
CFR is calculated as the unitless ratio between hyperemic to resting flow

Full Information

First Posted
August 19, 2008
Last Updated
July 25, 2014
Sponsor
K.Lance Gould
Collaborators
Gilead Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT00738049
Brief Title
Darusentan Effect on PET Uptake Heterogeneity
Acronym
Darusentan
Official Title
A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
K.Lance Gould
Collaborators
Gilead Sciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to test the hypothesis that myocardial perfusion heterogeneity, quantified by Markovian Homogeneity analysis of cardiac PET perfusion images, will improve in a quantitative manner after treatment with selective ETA receptor antagonist darusentan 100 mg per day for 2 weeks compared to baseline and post-treatment PET scans in clinically stable subjects with coronary atherosclerosis and/or risk factors.
Detailed Description
This 6-week, Phase 2, randomized, double-blind, crossover, investigator-initiated, single-center study will determine the feasibility of detecting the effect of darusentan 100 mg once daily on the extent of myocardial perfusion heterogeneity in subjects with documented CAD, as measured by cardiac PET imaging. Prior to the initiation of any study procedures, an Informed Consent Form and HIPAA Authorization will be reviewed and signed by each subject. Screening assessments and evaluations may be conducted over a period of not more than 4 weeks. Following a baseline PET scan (PET 1) subjects will be randomized to one of two treatment groups (Group 1 or Group 2), and receive blinded treatment for a total of 4 weeks. The 4-week treatment period will have two phases, Phase 1 and Phase 2. Group 1 will receive darusentan 100 mg for 2 weeks during Phase 1, then placebo for 2 weeks during Phase 2. Group 2 will receive placebo for 2 weeks during Phase 1, then darusentan 100 mg for 2 weeks during Phase 2. Following 4 weeks of treatment with blinded study drug, subjects in both treatment groups will be withdrawn from study drug for an additional 2 weeks. Maximum darusentan exposure in this study will be 2 weeks, and maximum placebo exposure in this study will be 2 weeks. Adjustments to the number or dosage of concomitant medications required for study entry will not be permitted at any time during the study. A physical exam will be done at baseline and week 6 as well as blood chemistry and hematology samples taken. Vital signs and any adverse events will be monitored at each visit. Efficacy will be assessed through cardiac PET imaging. In total, four PET scans will be administered: the first at the Randomization Visit (PET 1, Week 0); the second at the conclusion of Phase 1 (PET 2, Week 2); the third at the conclusion of Phase 2 (PET 3, Week 4) and the fourth at the conclusion of the Withdrawal period (PET 4, Week 6). Subjects will be instructed to take their study drug with or without food once daily at approximately the same time in the morning throughout the course of the study. Subjects will also be instructed to take all concomitant medications consistently and at the same time each day throughout the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Endothelial Dysfunction
Keywords
atherosclerosis, coronary artery disease, myocardial perfusion defect, endothelial dysfunction, endothelin receptor blockade

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Active Comparator
Arm Description
Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
Arm Title
Group 2
Arm Type
Active Comparator
Arm Description
Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
Intervention Type
Drug
Intervention Name(s)
darusentan 100 mg
Other Intervention Name(s)
darusentan, CID 177236, LU-135252, HMR-4005, 171714-84-4
Intervention Description
All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
Primary Outcome Measure Information:
Title
Change During Darusentan Treatment in the Markovian Homogeneity Number, a Value That Quantitates Myocardial Perfusion Heterogeneity
Description
Markovian homogeneity analysis characterizes an image produced by a PET scan by examining the probability that a pixel with a given intensity will have a neighbor with a different intensity. The homogeneity index ranges from >0 to 1, where a value near 0 represents an image with a high probability that neighboring pixels have intensity values that differ greatly, and a value near 1 represents an image with a high probability that neighboring pixels have similar intensity values.
Time Frame
0, 2, 4, and 6 weeks
Secondary Outcome Measure Information:
Title
Change During Darusentan Treatment in Absolute Flow at Rest and Hyperemia
Time Frame
0, 2, 4, and 6 weeks
Title
Change During Darusentan Treatment in the Coronary Flow Reserve (CFR)
Description
CFR is calculated as the unitless ratio between hyperemic to resting flow
Time Frame
0, 2, 4, and 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must be competent to provide written informed consent. Subjects must sign an IRB approved ICF and HIPAA Authorization prior to the initiation of any study procedures. All men must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking study drug, and queried regarding their understanding of the potential risks as described in the ICF. Subjects must be greater than 18 years of age. Female subjects must be surgically sterile or documented as post-menopausal for at least 2 years. Subjects must have documented coronary artery disease as evidenced by previous myocardial infarction, interventional procedure, significant stenosis by cardiac catheterization, or an abnormal perfusion study. Subjects must have an abnormal PET scan. Exclusion Criteria: Subjects with acute heart failure Subjects with sustained or symptomatic hypotension (SBP 90 mmHg) Subjects with uncontrolled hypertension (SBP of 170 mmHg or DBP of 100 mmHg) at Screening Subjects with unstable angina pectoris Subjects with acute myocardial infarction, stroke, transient ischemic attack, or coronary angioplasty within the last 6 months Subjects with primary valvular disease Subjects with significant vascular aneurysm Subjects with a documented history of renal failure Subjects with liver disease (total bilirubin 3 mg/dL or serum ALT or AST >2X ULN) Subjects with active malignancy Subjects with a fatal non-cardiovascular disease that they are expected to succumb to within 1 year Female subjects that are pregnant or lactating Female subjects with the potential for child-bearing Female subjects being treated with hormone therapies Subjects with uncontrolled diabetes mellitus Subjects with diabetes with gastro paresis or severe neuropathy Subjects with a history of substance abuse within the last 2 years Subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the Screening Visit Subjects with known hypersensitivity or allergy to L-arginine, aminophylline, adenosine, or dipyridamole Subjects who have a planned surgical procedure during the course of the study Subjects taking herbal food supplements (L-carnitine, L-arginine or Ginko biloba) Subjects with known active or dormant type 2 herpes simplex virus infections Subjects with a contraindication to treatment with an ERA. Contraindications may include, but are not limited to, evidence of elevated liver function tests (e.g., aminotransferases >2X ULN) or an event defined as a serious adverse event attributed to previous treatment with an ERA Subjects who are judged by the investigator to be ineligible for this study for any other reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
K Lance Gould, MD
Organizational Affiliation
University of Texas Medical School at Houston
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nils Johnson, MD
Organizational Affiliation
University of Texas Medical School at Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11827916
Citation
Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002 Feb 5;105(5):546-9. doi: 10.1161/hc0502.104540. No abstract available.
Results Reference
background
PubMed Identifier
9396430
Citation
Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 1997 Nov 18;96(10):3378-83. doi: 10.1161/01.cir.96.10.3378.
Results Reference
background
PubMed Identifier
10704159
Citation
Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000 Mar 7;101(9):948-54. doi: 10.1161/01.cir.101.9.948.
Results Reference
background
PubMed Identifier
10779454
Citation
Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000 Apr 25;101(16):1899-906. doi: 10.1161/01.cir.101.16.1899.
Results Reference
background
PubMed Identifier
12163423
Citation
Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002 Aug 6;106(6):653-8. doi: 10.1161/01.cir.0000025404.78001.d8.
Results Reference
background
PubMed Identifier
15136498
Citation
Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation. 2004 Jun 1;109(21):2518-23. doi: 10.1161/01.CIR.0000128208.22378.E3. Epub 2004 May 10.
Results Reference
background
PubMed Identifier
11222474
Citation
Bottcher M, Madsen MM, Refsgaard J, Buus NH, Dorup I, Nielsen TT, Sorensen K. Peripheral flow response to transient arterial forearm occlusion does not reflect myocardial perfusion reserve. Circulation. 2001 Feb 27;103(8):1109-14. doi: 10.1161/01.cir.103.8.1109.
Results Reference
background
PubMed Identifier
2923057
Citation
Nesto RW, Lamas GA, Barry J. Paradoxical elevation of threshold to angina pectoris by cold pressor test in men with significant coronary artery disease. Am J Cardiol. 1989 Mar 15;63(11):656-9. doi: 10.1016/0002-9149(89)90246-4.
Results Reference
background
PubMed Identifier
12515871
Citation
Kjaer A, Meyer C, Nielsen FS, Parving HH, Hesse B. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. J Nucl Med. 2003 Jan;44(1):19-23.
Results Reference
background
PubMed Identifier
8281679
Citation
el-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Conti CR, Pepine CJ. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothelial function revisited. Circulation. 1994 Jan;89(1):45-51. doi: 10.1161/01.cir.89.1.45.
Results Reference
background
PubMed Identifier
23842710
Citation
Johnson NP, Gould KL. Physiology of endothelin in producing myocardial perfusion heterogeneity: a mechanistic study using darusentan and positron emission tomography. J Nucl Cardiol. 2013 Oct;20(5):835-44. doi: 10.1007/s12350-013-9756-5. Epub 2013 Jul 11.
Results Reference
background

Learn more about this trial

Darusentan Effect on PET Uptake Heterogeneity

We'll reach out to this number within 24 hrs